In 2023, Derek J. Maetzold earned $1.61M in total compensation at Castle Biosciences, including $686.40K salary and $893.35K bonus. Most recently sold 58,354 shares in Mar 2025. Currently holds stock worth $1.82M. Has donated $12.25M in stock to charitable causes. Has led Castle Biosciences for over 18 years.
Compensation History
Annual executive compensation data for Derek J. Maetzold, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.61M
Salary
$686.40K
Bonus
$893.35K
Other
$26.23K
Salary
$686.40KBoard Justification
The compensation philosophy is designed to attract, retain, and motivate executive officers by offering competitive compensation packages that include a base salary, annual cash bonuses, and long-term equity incentive awards, aligned with market trends and industry data.
Bonus
$893.35KBoard Justification
The bonus for 2023 was based entirely on corporate performance goals, achieving 137% of the target bonus opportunity.
Other Compensation
$26.23KBoard Justification
Other compensation includes 401(k) matching contributions and financial advisory services.
Restricted Stock
Board Justification
No stock awards were granted in 2023; therefore, no stock vested in 2023.
Performance Metrics
The performance metrics for 2023 included revenue growth and achievement of corporate performance goals.
Derek J. Maetzold
Founder and CEO of Castle Biosciences
Education
B.S. degree in Biology from George Mason University and an MBA from University of California, Riverside.
Field of Expertise
Healthcare & Life Sciences - Life Sciences
Sector of Economy
Healthcare
CEO of Castle Biosciences for
18 years 2 months (Sep 2007 - Present)
Previous Experience
Held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis).
Holdings
Track Derek J. Maetzold's stock holdings and portfolio value over time.
Total Stock Sold
$84.06M
$84.06M
1,695,915 CSTL shares
What if they kept their stock?
If Derek J. Maetzold didn't sell their stock, today they would have:
Extra CSTL1,695,915 shares worth $44.08M.
This is -47.57% and $39.99M less than what they got when they sold the stock.
Charitable Transactions
471,284 shares
CSTL
Recent Charitable Transactions
122,181 shares
CSTL
Jan 10, 2022
Charity
349,103 shares
CSTL
Dec 31, 2020
Charity
Insider Trading
Derek J. Maetzold's recent stock transactions, purchases, and sales filed with the SEC.
$1.19M
CSTL at $20.34/share
Mar 7, 2025
Sale
$237.24K
CSTL at $20.86/share
Mar 4, 2025
Sale
$146.44K
CSTL at $28.55/share
Jan 13, 2025
Sale
$226.57K
CSTL at $29.47/share
Jan 6, 2025
Sale
$267.30K
CSTL at $28.55/share
Dec 17, 2024
Sale
$752.77K
CSTL at $28.82/share
Dec 13, 2024
Sale
$160.74K
CSTL at $31.35/share
Dec 5, 2024
Sale
$175.09K
CSTL at $34.15/share
Nov 12, 2024
Sale
$168.38K
CSTL at $32.84/share
Nov 4, 2024
Sale
$165.46K
CSTL at $32.27/share
Oct 14, 2024
Sale
Rivals
Compare Derek J. Maetzold with competitor CEOs and industry peers.